Basiliximab

CLINICAL USE

Chimeric murine/human monoclonal anti CD25 antibody:

Prophylaxis of acute allograft rejection in combination with maintenance immunosuppression

DOSE IN NORMAL RENAL FUNCTION

20 mg 2 hours before transplant and 20 mg 4 days after transplant

PHARMACOKINETICS

Molecular weight :Approx 144 000

%Protein binding :

%Excreted unchanged in urine : No data

Volume of distribution (L/kg) :4.5–12.7 litres

half-life – normal/ESRD (hrs) :4–10.4 days/Unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Not dialysed. Dose as in normal renal function

HD :Not dialysed. Dose as in normal renal function

HDF/high flux :Unknown dialysability. Dose as in normal renal function

CAV/VVHD :Not dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugsCiclosporin: may alter ciclosporin requirementsTacrolimus: may alter tacrolimus requirements

ADMINISTRATION

Reconstition

Reconstitute each vial with 5 mL water for injection then dilute to 50 mL or greater with sodium chloride 0.9% or glucose 5%

Route

IV infusion

Rate of Administration

20–30 minutes

Comments

–

OTHER INFORMATION

cinIn vitro studies indicate that basiliximab binds only to activated lymphocytes

Basiliximab is detectable in serum for up to 3 months after 15–25 mg doses

Use with caution in patients who have previously had basiliximab due to increased risk of developing hypersensitivity reactions.

Tags: post-by-auto-php